ARCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Arcturus Therapeutics Holdings Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.42+0.08 (+0.77%)
Close on Oct 19, 2026
- Market cap
- $296.17M
- P/E (TTM)
- –
- Dividend yield
- –
Arcturus Therapeutics Holdings Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grant Revenue [Member] | $2.08M | $1.45M | $4.12M | $3.00M | $3.79M | $3.91M | $1.77M | $2.86M | $3.88M | $5.41M | $5.78M | $1.76M | 70.3% | -45.2% |
| Collaboration Revenue [Member] | $880.00K | $610.00K | $3.08M | $14.15M | $24.51M | $25.48M | $21.00M | $38.82M | $45.98M | $32.60M | $25.08M | $43.38M | 29.7% | -96.4% |
By region
From the segment and revenue-disaggregation notes of Arcturus Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.